1. Regulations, liability, safety, and economics related to compounding;Campbell;J Am Acad Dermatol,2020
2. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503B of the federal Food, Drug, and Cosmetic Act. Updated January 27, 2022. Accessed March 5, 2022. https://www.fda.gov/media/94164/download
3. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides;Lessin;JAMA Dermatol,2013
4. Cantharidin revisited: a blistering defense of an ancient medicine;Moed;Arch Dermatol,2001
5. Food and Drug Administration. Facility definition under section 503B of the federal Food, Drug and Cosmetic Act. May 2018. Accessed April 3, 2022. https://www.fda.gov/media/97359/download#:∼:text=Section%20503B(d)%20defines%20an,compounding%20of%20human%20drug%20products